Top Authors

• Most frequent coverage on KERX

• 
  VFC's Stock House (1127 followers)

  • Still Believe in Antigenics (Tue, Nov 24)
  • Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News (Tue, Oct 27)
  • Keryx Biopharma Investors Should Wait for More News on Trials (Fri, Oct 9)

  More by VFC's Stock House on KERX »
• 
  Alan Brochstein (701 followers)

  • Cancer Stocks: Lagging Again (Mon, Jul 16)
  • Cancer Stocks Hammered Once Again (Tue, Jun 26)
  • Cancer Stocks Slide Again (Mon, Jun 18)

  More by Alan Brochstein on KERX »
• 
  Midnight Trader (179 followers)

  • Closing Update for Tuesday, Sept. 29: Dow Fronts Narrow Losses (Tue, Sep 29)
  • Closing Update: Stocks End at Day's Highs, Advance Eight Days Out of Nine (Wed, Sep 16)
  • Closing Update for Monday, August 3 (Mon, Aug 3)

  More by Midnight Trader on KERX »

• Most followed authors on KERX

• 
  Bespoke Investment Group (3425 followers)

  • Best and Worst Performing Stocks in the Russell 3,000 Year to Date (Fri, Jun 13)

  More by Bespoke Investment Group on KERX »
• 
  Market Folly (1903 followers)

  • SAC Capital Portfolio Update: 37 13G Filings (Thu, Jan 15)

  More by Market Folly on KERX »
• 
  Mike Havrilla (1901 followers)

  • FDA Calendar Updates: Transcept Pharma Surges on Deal (Mon, Aug 3)
  • FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results (Tue, Jun 9)

  More by Mike Havrilla on KERX »

• Newest authors on KERX

• 
  Justin M. Hall (667 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on KERX »
• 
  The Burrill Report (173 followers)

  • Biotech Busy with Bevy of Small Deals (Sat, Sep 12)

  More by The Burrill Report on KERX »
• 
  VFC's Stock House (1127 followers)

  • Still Believe in Antigenics (Tue, Nov 24)
  • Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News (Tue, Oct 27)
  • Keryx Biopharma Investors Should Wait for More News on Trials (Fri, Oct 9)

  More by VFC's Stock House on KERX »

• Most commented on KERX

• 
  Justin M. Hall (667 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on KERX »
• 
  VFC's Stock House (1127 followers)

  • Still Believe in Antigenics (Tue, Nov 24)
  • Keryx Biopharmaceuticals' Next Price Movers Will Be Trial News (Tue, Oct 27)
  • Keryx Biopharma Investors Should Wait for More News on Trials (Fri, Oct 9)

  More by VFC's Stock House on KERX »
• 
  Alan Brochstein (701 followers)

  • Cancer Stocks: Lagging Again (Mon, Jul 16)
  • Cancer Stocks Hammered Once Again (Tue, Jun 26)
  • Cancer Stocks Slide Again (Mon, Jun 18)

  More by Alan Brochstein on KERX »